Q-omics provides the consensus-scored C1orf94 profile across patient tissues and cancer cell-line models. C1orf94 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C1orf94 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, C1orf94 RNA expression shows 6,803 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, COAD, and STAD as cancer lineages where C1orf94 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1orf94 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1orf94 survival associations across molecular data types. C1orf94 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1orf94 RNA expression–survival associations across cancer types. High C1orf94 expression shows unfavorable associations in KIRC, STAD, KIRP and UVM, but favorable associations in ACC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C1orf94 RNA expression.
This table summarizes C1orf94 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for C1orf94. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1orf94 shows lower tumor expression in COAD, BLCA and STAD and higher tumor expression in CHOL, LUSC and LUAD. The COAD box plot shows higher C1orf94 RNA expression in normal versus tumor tissue (log2 FC = −0.055, t-test p < 0.001).
This table shows molecular features associated with C1orf94 in patient tissues and cancer cell lines. In patient samples, C1orf94 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, C1orf94 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
